Interleukin-16: The ins and outs of regulating T-cell activation

Critical Reviews in Immunology

Volumn 28, Issue 6, 2008, Pages 467-483

  Cruikshank, William ^a   Little, Frederic ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotaxis; Inflammation; Skp2 regulation; T cell growth

Indexed keywords

CASPASE 3; CD4 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GA BINDING PROTEIN; GA BINDING PROTEIN BETA; GA BINDING PROTEIN BETA1; HEAT SHOCK COGNATE PROTEIN 70; HISTONE DEACETYLASE 3; INTERLEUKIN 15; INTERLEUKIN 16; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P56; RANTES; S PHASE KINASE ASSOCIATED PROTEIN 2; STROMAL CELL DERIVED FACTOR 1; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; CHEMOKINE RECEPTOR; INTERLEUKIN 16 PRECURSOR; PROTEIN PRECURSOR;

AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CYCLE PROGRESSION; DENDRITIC CELL; GENE; GENE EXPRESSION; GENE SEQUENCE; GENE STRUCTURE; HUMAN; IL 16 GENE; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; ANIMAL; CHEMISTRY; CHEMOTAXIS; GENETICS; IMMUNOLOGY; METABOLISM; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS, CD4; CHEMOTAXIS; DENDRITIC CELLS; HUMANS; INTERLEUKIN-16; PROTEIN PRECURSORS; RECEPTORS, CHEMOKINE; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS;

EID: 62449219387     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Liu Y, Cruikshank WW, O'Loughlin T, O'Reilly P, Center DM, Kornfeld H. Identification of a CD4 domain required for interleukin-16 binding and lymphocyte activation. J Biol Chem. 1999 Aug 13;274(33):23387-95.
2. Wu H, Kwong PD, Hendrickson WA. Dimeric association and segmental variability in the structure of human CD4. Nature. 1997 May 29;387(6632):527-30.
3. Gratton S, Haughn L, Sekaly RP, Julius M. The extracellular domain of CD4 regulates the initiation of T cell activation. Mol Immunol. 2000 Apr;37(5):213-9.
4. Kim HS. Assignment of human interleukin 16 (IL16) to chromosome 15q26.3 by radiation hybrid mapping. Cytogenet Cell Genet. 1999;84(1-2):93.
5. Bannert N, Kurth R, Baier M. The gene encoding mouse interleukin-16 consists of seven exons and maps to chromosome 7 D2-D3. Immunogenetics. 1999 Jul;49(7-8):704-6.
6. Lim KG, Wan HC, Bozza PT, Resnick MB, Wong DT, Cruikshank WW, Kornfeld H, Center DM, Weller PF. Human eosinophils elaborate the lymphocyte chemoattractants. IL-16 (lymphocyte chemoattractant factor) and RANTES. J Immunol. 1996 Apr 1;156(7):2566-70.
7. Rumsaeng V, Cruikshank WW, Foster B, Prussin C, Kirshenbaum AS, Davis TA, Kornfeld H, Center DM, Metcalfe DD. Human mast cells produce the CD4+ T lymphocyte chemoattractant factor, IL-16. J Immunol. 1997 Sep 15;159(6):2904-10.
8. Kaser A, Dunzendorfer S, Offner FA, Ryan T, Schwabegger A, Cruikshank WW, Wiedermann CJ, Tilg H. A role for IL-16 in the cross-talk between dendritic cells and T cells. J Immunol. 1999 Sep 15;163(6):3232-8.
9. Sciaky D, Brazer W, Center DM, Cruikshank WW, Smith TJ. Cultured human fibroblasts express constitutive IL-16 mRNA: cytokine induction of active IL-16 protein synthesis through a caspase-3-dependent mechanism. J Immunol. 2000 Apr 1;164(7):3806-14.
10. Pritchard J, Tsui S, Horst N, Cruikshank WW, Smith TJ. Synovial fibroblasts from patients with rheumatoid arthritis, like fibroblasts from Graves' disease, express high levels of IL-16 when treated with Igs against insulin-like growth factor-1 receptor. J Immunol. 2004 Sep 1;173(5):3564-9.
11. Laberge S, Pinsonneault S, Varga EM, Till SJ, Nouri-Aria K, Jacobson M, Cruikshank WW, Center DM, Hamid Q, Durham SR. Increased expression of IL-16 immunoreactivity in bronchial mucosa after segmental allergen challenge in patients with asthma. J Allergy Clin Immunol. 2000 Aug;106(2):293-301.
12. Little FF, Cruikshank WW, Center DM. IL-9 stimulates release of chemotactic factors from human bronchial epithelial cells. Am J Respir Cell Mol Biol. 2001 Sep;25(3):347-52.
13. Zhang Y, Center DM, Wu DM, Cruikshank WW, Yuan J, Andrews DW, Kornfeld H. Processing and activation of pro-interleukin-16 by caspase-3. J Biol Chem. 1998 Jan 9;273(2):1144-9.
14. Kurschner C, Yuzaki M. Neuronal interleukin-16 (NIL-16): a dual function PDZ domain protein. J Neurosci. 1999 Sep 15;19(18):7770-80.
15. Wu DM, Zhang Y, Parada NA, Kornfeld H, Nicoll J, Center DM, Cruikshank WW. Processing and release of IL-16 from CD4+ but not CD8+ T cells is activation dependent. J Immunol. 1999 Feb 1;162(3):1287-93.
16. Reich K, Heine A, Hugo S, Blaschke V, Middel P, Kaser A, Tilg H, Blaschke S, Gutgesell C, Neumann C. Engagement of the Fc epsilon RI stimulates the production of IL-16 in Langerhans cell-like dendritic cells. J Immunol. 2001 Dec 1;167(11):6321-9.
17. Muhlhahn P, Zweckstetter M, Georgescu J, Ciosto C, Renner C, Lanzendorfer M, Lang K, Ambrosius D, Baier M, Kurth R, Holak TA. Structure of interleukin 16 resembles a PDZ domain with an occluded peptide binding site. Nat Struct Biol. 1998 Aug;5(8):682-6.
18. Baier M, Bannert N, Werner A, Lang K, Kurth R. Molecular cloning, sequence, expression, and processing of the interleukin 16 precursor. Proc Natl Acad Sci U S A. 1997 May 13;94(10):5273-7.
19. Wilson KC, Cruikshank WW, Center DM, Zhang Y. Prointerleukin-16 contains a functional CcN motif that regulates nuclear localization. Biochemistry. 2002 Dec 3;41(48):14306-12.
20. Bannert N, Vollhardt K, Asomuddinov B, Haag M, Konig H, Norley S, Kurth R. PDZ domain-mediated interaction of interleukin-16 precursor proteins with myosin phosphatase targeting subunits. J Biol Chem. 2003 Oct 24;278(43):42190-9.
21. Nicoll J, Cruikshank WW, Brazer W, Liu Y, Center DM, Kornfeld H. Identification of domains in IL-16 critical for biological activity. J Immunol. 1999 Aug 15;163(4):1827-32.
22. Zhang Y, Tuzova M, Xiao ZX, Cruikshank WW, Center DM. Pro-IL-16 recruits histone deacetylase 3 to the Skp2 core promoter through interaction with transcription factor GABP. J Immunol. 2008 Jan 1;180(1):402-8.
23. Zhang Y, Kornfeld H, Cruikshank WW, Kim S, Reardon CC, Center DM. Nuclear translocation of the N-terminal prodomain of interleukin-16. J Biol Chem. 2001 Jan 12;276(2):1299-303.
24. Stevenson FT, Turck J, Locksley RM, Lovett DH. The N-terminal propiece of interleukin 1 alpha is a transforming nuclear oncoprotein. Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):508-13.
25. Cruikshank WW, Center DM, Nisar N, Wu M, Natke B, Theodore AC, Kornfeld H. Molecular and functional analysis of a lymphocyte chemoattractant factor: association of biologic function with CD4 expression. Proc Natl Acad Sci U S A. 1994 May 24;91(11):5109-13.
26. Wilson KC, Cattel DJ, Wan Z, Rahangdale S, Ren F, Kornfeld H, Sullivan BA, Cruikshank WW, Center DM. Regulation of nuclear prointerleukin-16 and p27(Kip1) in primary human T lymphocytes. Cell Immunol. 2005 Sep;237(1):17-27.
27. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol. 1999 Aug;1(4):193-9.
28. Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol. 1999 Jun 17;9(12):661-4.
29. Center DM, Cruikshank WW, Zhang Y. Nuclear pro-IL-16 regulation of T cell proliferation: p27(KIP1)-dependent G0/G1 arrest mediated by inhibition of Skp2 transcription. J Immunol. 2004 Feb 1;172(3):1654-60.
30. Latres E, Chiarle R, Schulman BA, Pavletich NP, Pellicer A, Inghirami G, Pagano M. Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2515-20.
31. Yang J, Liu CQ. Interaction between human interleukin-16 and CD4 receptor of HIV-1. Acta Pharmacol Sin. 2000 Jun;21(6):547-53.
32. Kitchen SG, LaForge S, Patel VP, Kitchen CM, Miceli MC, Zack JA. Activation of CD8 T cells induces expression of CD4, which functions as a chemotactic receptor. Blood. 2002 Jan 1;99(1):207-12.
33. Mathy NL, Bannert N, Norley SG, Kurth R. Cutting edge: CD4 is not required for the functional activity of IL-16. J Immunol. 2000 May 1;164(9):4429-32.
34. Stoitzner P, Ratzinger G, Koch F, Janke K, Scholler T, Kaser A, Cruikshank WW, Fritsch P, Romani N. Interleukin-16 supports the migration of Langerhans cells, partly in a CD4-independent way. J Invest Dermatol. 2001 May;116(5):641-9.
35. Lynch EA, Heijens CA, Horst NF, Center DM, Cruikshank WW. Cutting edge: IL-16/CD4 preferentially induces Th1 cell migration: requirement of CCR5. J Immunol. 2003 Nov 15;171(10):4965-8.
36. Ryan TC, Cruikshank WW, Kornfeld H, Collins TL, Center DM. The CD4-associated tyrosine kinase p56lck is required for lymphocyte chemoattractant factor-induced T lymphocyte migration. J Biol Chem. 1995 Jul 21;270(29):17081-6.
37. Parada NA, Cruikshank WW, Danis HL, Ryan TC, Center DM. IL-16- and other CD4 ligand-induced migration is dependent upon protein kinase C. Cell Immunol. 1996 Feb 25;168(1):100-6.
38. Rand TH, Cruikshank WW, Center DM, Weller PF. CD4-mediated stimulation of human eosinophils: lymphocyte chemoattractant factor and other CD4-binding ligands elicit eosinophil migration. J Exp Med. 1991 Jun 1;173(6):1521-8.
39. Cruikshank W, Center DM. Modulation of lymphocyte migration by human lymphokines. II. Purification of a lymphotactic factor (LCF). J Immunol. 1982 Jun;128(6):2569-74.
40. Mashikian MV, Ryan TC, Seman A, Brazer W, Center DM, Cruikshank WW. Reciprocal desensitization of CCR5 and CD4 is mediated by IL-16 and macrophage-inflammatory protein-1 beta, respectively. J Immunol. 1999 Sep 15;163(6):3123-30.
41. Cicala C, Arthos J, Ruiz M, Vaccarezza M, Rubbert A, Riva A, Wildt K, Cohen O, Fauci AS. Induction of phosphorylation and intracellular association of CC chemokine receptor 5 and focal adhesion kinase in primary human CD4+ T cells by macrophage-tropic HIV envelope. J Immunol. 1999 Jul 1;163(1):420-6.
42. Wong M, Uddin S, Majchrzak B, Huynh T, Proudfoot AE, Platanias LC, Fish EN. Rantes activates Jak2 and Jak3 to regulate engagement of multiple signaling pathways in T cells. J Biol Chem. 2001 Apr 6;276(14):11427-31.
43. Van Drenth C, Jenkins A, Ledwich L, Ryan TC, Mashikian MV, Brazer W, Center DM, Cruikshank WW. Desensitization of CXC chemokine receptor 4, mediated by IL-16/CD4, is independent of p56lck enzymatic activity. J Immunol. 2000 Dec 1;165(11):6356-63.
44. Szabo P, Zhao K, Kirman I, Le Maoult J, Dyall R, Cruikshank W, Weksler ME. Maturation of B cell precursors is impaired in thymic-deprived nude and old mice. J Immunol. 1998 Sep 1;161(5):2248-53.
45. Qi JC, Stevens RL, Wadley R, Collins A, Cooley M, Naif HM, Nasr N, Cunningham A, Katsoulotos G, Wanigasek Y, Roufogalis B, Krilis SA. IL-16 regulation of human mast cells/basophils and their susceptibility to HIV-1. J Immunol. 2002 Apr 15;168(8):4127-34.
46. Parada NA, Center DM, Kornfeld H, Rodriguez WL, Cook J, Vallen M, Cruikshank WW. Synergistic activation of CD4+ T cells by IL-16 and IL-2. J Immunol. 1998 Mar 1;160(5):2115-20.
47. Theodore AC, Center DM, Nicoll J, Fine G, Kornfeld H, Cruikshank WW. CD4 ligand IL-16 inhibits the mixed lymphocyte reaction. J Immunol. 1996 Sep 1;157(5):1958-64.
48. Cruikshank WW, Lim K, Theodore AC, Cook J, Fine G, Weller PF, Center DM. IL-16 inhibition of CD3-dependent lymphocyte activation and proliferation. J Immunol. 1996 Dec 15;157(12):5240-8.
49. de Bie JJ, Jonker EH, Henricks PA, Hoevenaars J, Little FF, Cruikshank WW, Nijkamp FP, Van Oosterhout AJ. Exogenous interleukin-16 inhibits antigen-induced airway hyper-reactivity, eosinophilia and Th2-type cytokine production in mice. Clin Exp Allergy. 2002 Nov;32(11):1651-8.
50. Laberge S, Ernst P, Ghaffar O, Cruikshank WW, Kornfeld H, Center DM, Hamid Q. Increased expression of interleukin-16 in bronchial mucosa of subjects with atopic asthma. Am J Respir Cell Mol Biol. 1997 Aug;17(2):193-202.
51. Hessel EM, Cruikshank WW, Van Ark I, de Bie JJ, Van Esch B, Hofman G, Nijkamp FP, Center DM, Van Oosterhout AJ. Involvement of IL-16 in the induction of airway hyperresponsiveness and up-regulation of IgE in a murine model of allergic asthma. J Immunol. 1998 Mar 15;160(6):2998-3005.
52. Busse WW, Lemanske RF Jr. Asthma. N Engl J Med. 2001 Feb 1;344(5):350-62.
53. Pinsonneault S, El Bassam S, Mazer B, Cruikshank WW, Laberge S. IL-16 inhibits IL-5 production by antigen-stimulated T cells in atopic subjects. J Allergy Clin Immunol. 2001 Mar;107(3):477-82.
54. McFadden C, Morgan R, Rahangdale S, Green D, Yamasaki H, Center D, Cruikshank WW. Preferential migration of T regulatory cells induced by IL-16. J Immunol. 2007 Nov 15;179(10):6439-45.
55. Ferland C, Flamand N, Davoine F, Chakir J, Laviolette M. IL-16 activates plasminogen-plasmin system and promotes human eosinophil migration into extracellular matrix via CCR3-chemokine-mediated signaling and by modulating CD4 eosinophil expression. J Immunol. 2004 Oct 1;173(7):4417-24.
56. Rand TH, Silberstein DS, Kornfeld H, Weller PF. Human eosinophils express functional interleukin 2 receptors. J Clin Invest. 1991 Sep;88(3):825-32.
57. Bandeira-Melo C, Sugiyama K, Woods LJ, Phoofolo M, Center DM, Cruikshank WW, Weller PF. IL-16 promotes leukotriene C(4) and IL-4 release from human eosinophils via CD4- and autocrine CCR3-chemokine-mediated signaling. J Immunol. 2002 May 1;168(9):4756-63.
58. Cruikshank WW, Berman JS, Theodore AC, Bernardo J, Center DM. Lymphokine activation of T4+ T lymphocytes and monocytes. J Immunol. 1987 Jun 1;138(11):3817-23.
59. Della BS, Nicola S, Timofeeva I, Villa ML, Santoro A, Berardi AC. Are interleukin-16 and thrombopoietin new tools for the in vitro generation of dendritic cells? Blood. 2004 Dec 15;104(13):4020-8.
60. Reich K, Hugo S, Middel P, Blaschke V, Heine A, Neumann C. The maturation-dependent production of interleukin-16 is impaired in monocyte-derived dendritic cells from atopic dermatitis patients but is restored by inflammatory cytokines TNF-alpha and IL-1beta. Exp Dermatol. 2004 Dec;13(12):740-7.
61. Keates AC, Castagliuolo I, Cruickshank WW, Qiu B, Arseneau KO, Brazer W, Kelly CP. Interleukin 16 is up-regulated in Crohn's disease and participates in TNBS colitis in mice. Gastroenterology. 2000 Oct;119(4):972-82.
62. Pallone F, Monteleone G. Mechanisms of tissue damage in inflammatory bowel disease. Curr Opin Gastroenterol. 2001 Jul;17(4):307-12.
63. Tzianabos AO, Holsti MA, Zheng XX, Stucchi AF, Kuchroo VK, Strom TB, Glimsher LH, Cruikshank WW. Functional Th1 cells are required for surgical adhesion formation in a murine model. J Immunol. 2008 May 15;180(10):6970-6.
64. Wang S, Diao H, Guan Q, Cruikshank WW, Delovitch TL, Jevnikar AM, Du C. Decreased renal ischemia-reperfusion injury by IL-16 inactivation. Kidney Int. 2008 Feb;73(3):318-26.
65. Skundric DS, Zhou W, Cruikshank WW, Dai R. Increased levels of bioactive IL-16 correlate with disease activity during relapsing experimental autoimmune encephalomyelitis (EAE). J Autoimmun. 2005 Nov;25(3):206-14.
66. Skundric DS, Dai R, Zakarian VL, Bessert D, Skoff RP, Cruikshank WW, Kurjakovic Z. Anti-IL-16 therapy reduces CD4+ T-cell infiltration and improves paralysis and histopathology of relapsing EAE. J Neurosci Res. 2005 Mar 1;79(5):680-93.
67. Laberge S, Pinsonneault S, Ernst P, Olivenstein R, Ghaffar O, Center DM, Hamid Q. Phenotype of IL-16-producing cells in bronchial mucosa: evidence for the human eosinophil and mast cell as cellular sources of IL-16 in asthma. Int Arch Allergy Immunol. 1999 Jun;119(2):120-5.
68. Mashikian MV, Tarpy RE, Saukkonen JJ, Lim KG, Fine GD, Cruikshank WW, Center DM. Identification of IL-16 as the lymphocyte chemotactic activity in the bronchoalveolar lavage fluid of histamine-challenged asthmatic patients. J Allergy Clin Immunol. 1998 Jun;101(6 Pt 1):786-92.
69. Laberge S, Durham SR, Ghaffar O, Rak S, Center DM, Jacobson M, Hamid Q. Expression of IL-16 in allergen-induced late-phase nasal responses and relation to topical glucocorticosteroid treatment. J Allergy Clin Immunol. 1997 Oct;100(4):569-74.
70. Cruikshank WW, Long A, Tarpy RE, Kornfeld H, Carroll MP, Teran L, Holgate ST, Center DM. Early identification of interleukin-16 (lymphocyte chemoattractant factor) and macrophage inflammatory protein 1 alpha (MIP1 alpha) in bronchoalveolar lavage fluid of antigen-challenged asthmatics. Am J Respir Cell Mol Biol. 1995 Dec;13(6):738-47.
71. El BS, Pinsonneault S, Kornfeld H, Ren F, Menezes J, Laberge S. Interleukin-16 inhibits interleukin-13 production by allergen-stimulated blood mononuclear cells. Immunology. 2006 Jan;117(1):89-96.
72. Trudelle A, El BS, Pinsonneault S, Mazer B, Laberge S. Interleukin-16 inhibits immunoglobulin e production by B lymphocytes. Int Arch Allergy Immunol. 2007;143(2):109-18.
73. Glass WG, Sarisky RT, Vecchio AM. Not-so-sweet sixteen: the role of IL-16 in infectious and immune-mediated inflammatory diseases. J Interferon Cytokine Res. 2006 Aug;26(8):511-20.
74. Wilson KC, Center DM, Cruikshank WW. The effect of interleukin-16 and its precursor on T lymphocyte activation and growth. Growth Factors. 2004 Jun;22(2):97-104.
75. Burkart KM, Barton SJ, Holloway JW, Yang IA, Cakebread JA, Cruikshank W, Little F, Jin X, Farrer LA, Clough JB, Keith TP, Holgate ST, Center DM, O'Connor GT. Association of asthma with a functional promoter polymorphism in the IL16 gene. J Allergy Clin Immunol. 2006 Jan;117(1):86-91.
76. Masuda K, Katoh N, Okuda F, Kishimoto S. Increased levels of serum interleukin-16 in adult type atopic dermatitis. Acta Derm Venereol. 2003;83(4):249-53.
77. Bussmann C, Maintz L, Hart J, Allam JP, Vrtala S, Chen KW, Bieber T, Thomas WR, Valenta R, Zuberbier T, Sager A, Novak N. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study. Clin Exp Allergy. 2007 Sep;37(9):1277-85.
78. Cho ML, Jung YO, Kim KW, Park MK, Oh HJ, Ju JH, Cho YG, Min JK, Kim SI, Park SH, Kim HY. IL-17 induces the production of IL-16 in rheumatoid arthritis. Exp Mol Med. 2008 Apr 30;40(2):237-45.
79. Lard LR, Roep BO, Toes RE, Huizinga TW. Enhanced concentrations of interleukin 16 are associated with joint destruction in patients with rheumatoid arthritis. J Rheumatol. 2004 Jan;31(1):35-9.
80. Seegert D, Rosenstiel P, Pfahler H, Pfefferkorn P, Nikolaus S, Schreiber S. Increased expression of IL-16 in inflammatory bowel disease. Gut. 2001 Mar;48(3):326-32.
81. Tranquilli AL, Landi B, Corradetti A, Giannubilo SR, Sartini D, Pozzi V, Emanuelli M. Inflammatory cytokines patterns in the placenta of pregnancies complicated by HELLP (hemolysis, elevated liver enzyme, and low platelet) syndrome. Cytokine. 2007 Nov;40(2):82-8.
82. Hu W, Wang H, Wang Z, Huang H, Dong M. Elevated serum levels of interleukin-15 and interleukin-16 in preeclampsia. J Reprod Immunol. 2007 Apr;73(2):166-71.
83. Devadas K, Zhou P, Tewari D, Notkins AL. Inhibition of HIV-1 replication by the combined action of anti-gp41 single chain antibody and IL-16. Antiviral Res. 2003 Jun;59(1):67-70.
84. Truong MJ, Darcissac EC, Hermann E, Dewulf J, Capron A, Bahr GM. Interleukin-16 inhibits human immunodeficiency virus type 1 entry and replication in macrophages and in dendritic cells. J Virol. 1999 Aug;73(8):7008-13.
85. Maciaszek JW, Parada NA, Cruikshank WW, Center DM, Kornfeld H, Viglianti GA. IL-16 represses HIV-1 promoter activity. J Immunol. 1997 Jan 1;158(1):5-8.
86. Asadullah K, Haeussler-Quade A, Gellrich S, Hanneken S, Hansen-Hagge TE, Docke WD, Volk HD, Sterry W. IL-15 and IL-16 overexpression in cutaneous T-cell lymphomas: stage-dependent increase in mycosis fungoides progression. Exp Dermatol. 2000 Aug;9(4):248-51.
87. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, Yu K, Chatterjee N, Welch R, Hutchinson A, Crenshaw A, Cancel-Tassin G, Staats BJ, Wang Z, Gonzalez-Bosquet J, Fang J, Deng X, Berndt SI, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cussenot O, Valeri A, Andriole GL, Crawford ED, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover R, Hayes RB, Hunter DJ, Chanock SJ. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet. 2008 Mar;40(3):310-5.